Revision of Previously Issued Financial Statements - Schedule of condensed Consolidated Balance Sheet (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Condensed Consolidated Balance Sheet
Additional paid-in capital	$ 297,119		$ 292,082
Accumulated deficit	(177,025)		(149,232)
Condensed Consolidated Statement of Comprehensive Loss
Cost of Revenue	58,840	$ 65,588
Research and development	2,701	1,954
Selling and marketing	1,972	1,100
General and administrative	13,818	5,084
Total operating expenses	18,491	8,138
Loss from operations	(27,778)	(8,019)
Loss before income taxes	(27,717)	(7,461)
Net loss	(27,793)	(7,442)
Comprehensive loss	$ (27,736)	$ (7,443)
Basic loss per share	$ (0.28)	$ (0.11)
Diluted loss per share	$ (0.28)	$ (0.11)
Basic weighted-average number of common shares outstanding	99,211,792	66,875,469
Diluted weighted-average number of common shares outstanding	99,211,792	66,875,469
Statement of Stockholders' Equity [Abstract]
Net Income (loss)	$ (27,793)	$ (7,442)
Stockholders equity	120,168	496	142,866	$ 7,451
Statement of Cash Flows [Abstract]
Net loss	$ (27,793)	$ (7,442)
Note 11. Net loss per share
Potential common shares excluded from diluted net loss per share	13,448,111	23,660,000
Product
Condensed Consolidated Statement of Comprehensive Loss
Cost of Revenue	$ 34,963	$ 54,996
Additional Paid-in Capital
Statement of Stockholders' Equity [Abstract]
Stockholders equity	297,119	50,584	292,082	50,096
Accumulated Deficit
Condensed Consolidated Statement of Comprehensive Loss
Net loss	(27,793)	(7,442)
Statement of Stockholders' Equity [Abstract]
Net Income (loss)	(27,793)	(7,442)
Stockholders equity	(177,025)	(50,085)	$ (149,232)	$ (42,643)
Statement of Cash Flows [Abstract]
Net loss	$ (27,793)	$ (7,442)